Potential of hybrid iron oxide–gold nanoparticles as thermal triggers for pancreatic cancer therapy

Oluwasanmi, Adeolu; Malekigorji, Maryam; Jones, Stephanie B.; Curtis, A. D. M.; Hoskins, Clare

doi:10.1039/c6ra20552f

Cited by 13 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study that evaluated the potential of poly(ethylene glycol) coated hybrid iron nanoparticles as heat triggers for PC therapy looked at both the in vitro and in vivo outcome of administered hybrid nanoparticles and production of heat shock proteins (HSP-27 and HSP-70) which are produced under heat-related stressful conditions in cells [ 158 ]. These proteins are classed as molecular chaperones that assist various protein folding processes such as the folding of newly synthesised proteins and the refolding of misfolded proteins [ 159 ].…”

Section: Nanotechnologies In Pancreatic Cancermentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnologies in Pancreatic Cancer Therapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

Pancreatic cancer has been classified as a cancer of unmet need. After diagnosis the patient prognosis is dismal with few surviving over 5 years. Treatment regimes are highly patient variable and often the patients are too sick to undergo surgical resection or chemotherapy. These chemotherapies are not effective often because patients are diagnosed at late stages and tumour metastasis has occurred. Nanotechnology can be used in order to formulate potent anticancer agents to improve their physicochemical properties such as poor aqueous solubility or prolong circulation times after administration resulting in improved efficacy. Studies have reported the use of nanotechnologies to improve the efficacy of gemcitabine (the current first line treatment) as well as investigating the potential of using other drug molecules which have previously shown promise but were unable to be utilised due to the inability to administer through appropriate routes—often related to solubility. Of the nanotechnologies reported, many can offer site specific targeting to the site of action as well as a plethora of other multifunctional properties such as image guidance and controlled release. This review focuses on the use of the major nanotechnologies both under pre-clinical development and those which have recently been approved for use in pancreatic cancer therapy.

show abstract

Section: Nanotechnologies In Pancreatic Cancermentioning

confidence: 99%

“…At 50 µg·mL −1 HNP, cell viability fell to 85% after multiple laser irradiations. Upon intra-tumoral injection in pancreatic xenograft models, a similar heating capacity was observed at identical concentration which also resulted in bulk tumour dissipation [ 158 ].…”

Section: Nanotechnologies In Pancreatic Cancermentioning

confidence: 99%

Nanotechnologies in Pancreatic Cancer Therapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…We have fabricated HNPs and demonstrated their potential for imaging using magnetic resonance imaging [25], heating after laser irradiation (by exploitation of surface plasmon resonance) in phantoms that mimic biological systems [26], in vitro [27] and in vivo [19]. We have also reported the use of these HNPs as drug carrier vehicles [28] and have demonstrated their utility as heat initiated drug release vehicles [19].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy

Oluwasanmi

Al-Shakarchi

Manzur

et al. 2017

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

Hybrid nanoparticles (HNPs) have shown huge potential as drug delivery vehicles for pancreatic cancer. Currently, the first line treatment, gemcitabine, is only effective in 23.8% of patients. To improve this, a thermally activated system was developed by introducing a linker between HNPs and gemcitabine. Whereby, heat generation resulting from laser irradiation of the HNPs promoted linker breakdown resulting in prodrug liberation. In vitro evaluation in pancreatic adenocarcinoma cells, showed the prodrug was 4.3 times less cytotoxic than gemcitabine, but exhibited 11-fold improvement in cellular uptake. Heat activation of the formulation led to a 56% rise in cytotoxicity causing it to outperform gemcitabine by 26%. In vivo the formulation outperformed free gemcitabine with a 62% reduction in tumor weight in pancreatic xenografts. This HNP formulation is the first of its kind and has displayed superior anti-cancer activity as compared to the current first line drug gemcitabine after heat mediated controlled release.

show abstract

“…In order to exploit the thermo-responsive properties of these formulations, laser irradiation was used. Extensive previous studies have been carried out in order to optimize the laser treatment duration in order to achieve temperatures that are likely to initiate drug release without adverse effects to tissue [34,35]. Figure 6 A 1 shows a tumour excised from a control group mouse.…”

Section: In Vivo Evaluationmentioning

confidence: 99%

“…The HNP preparation and characterisation has been reported previously [21,22] along with their ability to undergo triggered heating upon laser irradiation in agar phantoms [17,34], in vitro and in situ in tumour bearing mouse cadavers [35,36]. Drug attachment was carried out at three drug:HNP weight ratios (5:1, 2.5:1 and 1:1 based on Fe weight of HNP) for all four bisnaphthalamide based drugs.…”

Section: Hnp-drug Conjugation and Characterisationmentioning

confidence: 99%

Thermally triggered theranostics for pancreatic cancer therapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

Hybrid iron oxide-gold nanoparticles (HNPs) are capable of drug binding onto their surface with a triggered release at elevated temperatures. The iron oxide core allows for diagnostic imaging whilst heating of the gold shell upon laser irradiation reverses drug binding. This study exploits the reversible binding of novel polyamine based drugs in order to provide specific and effective method for pancreatic cancer treatment. Here we used novel bisnaphthalamido (BNIP) based drug series. Our hybrid nanoparticles (50 nm) were capable of drug loading onto their surface (3:1:0.25, Drug:Fe:Au). By exploiting the surface-to-drug electrostatic interaction of a range of BNIP agents, heat triggered drug release was achieved.12-fold reduction in IC 50 after 24 h in vitro and 5-fold reduction of tumour retardation in vivo compared with free drug in pancreatic models after treatment with the HNP-formulation and laser irradiation. This heat activated system could provide a key platform for future therapy strategies.

show abstract

Potential of hybrid iron oxide–gold nanoparticles as thermal triggers for pancreatic cancer therapy

Abstract: Laser irradiation of hybrid nanoparticles in biological conditions for future application in pancreatic cancer therapy.

Cited by 13 publications

References 23 publications

Nanotechnologies in Pancreatic Cancer Therapy

Nanotechnologies in Pancreatic Cancer Therapy

Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy

Thermally triggered theranostics for pancreatic cancer therapy

Contact Info

Product

Resources

About